Cardiovascular Considerations in Stimulant Therapy

Introduction to Stimulant-Induced Cardiovascular Changes

• Stimulant medications commonly cause mild increases in heart rate (1-2 beats per minute) and blood pressure (1-4 mmHg), with 5-15% of patients experiencing more substantial increases, according to the American Academy of Pediatrics 1, 2
• Alternative causes of tachycardia, such as anxiety, dehydration, fever, or anemia, should be considered rather than attributing all tachycardia to stimulants, as recommended by the American College of Cardiology and the American Heart Association 3, 4

Management of Cardiovascular Risks

• Asymptomatic patients without cardiac risk factors can continue current stimulant medication with careful monitoring of vital signs at follow-up visits, according to the American Academy of Pediatrics 1, 2
• A heart rate consistently >120 bpm at rest, or the development of symptoms such as chest pain, unexplained syncope, or palpitations, warrants further evaluation, as suggested by the American College of Cardiology 3
• Routine ECG screening is not necessary before starting stimulant medication in children without cardiac risk factors, as stated by the American Academy of Pediatrics, due to the low risk of serious cardiovascular events with stimulant use in otherwise healthy children 2, 5
• A thorough cardiac history, including personal and family history, and baseline vital signs, is recommended before starting stimulant medication, along with monitoring at follow-up visits, to identify potential cardiac risk factors 2, 6
• Patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems should not use stimulants, according to the American Academy of Pediatrics 2
• Patients with a family history of sudden death, cardiac arrhythmias, hypertrophic cardiomyopathy, long QT syndrome, and Wolff-Parkinson-White syndrome require careful evaluation and consideration of factors such as heart rate, heart murmur, and personal and family history of cardiac symptoms 2, 7
• Healthcare providers should be alert for emerging cardiac symptoms during treatment with stimulants and consider additional cardiac evaluation, including ECG and possible referral to a pediatric cardiologist, if cardiac risk factors are present 2